Baylor College of Medicine

DECIST: Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma (H-42434)



The primary objective of this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate plus mRNA to pancreatic cancer patients as adjuvant therapy following completion of standard chemotherapy.

Patients will first complete standard treatment for pancreatic adenocarcinoma which is surgically resectable and then within 3 months of finishing chemotherapy, they will have three doses of the dendritic cell vaccine by perinodal injection using ultrasound guidance.

For more information:

IRB: H-42434




Back to topback-to-top